This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented ...

Because Arvinas made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually ...

Arvinas is a cash rich company, reporting current assets of >$1bn when announcing its Q3 earnings on November 7th. The company's cash burn is considerable however, with a net loss of $ (64m ...

Arvinas' shares have experienced a significant increase, up more than 75% since November 2023, due to the success of its lead asset, vepdegestrant, in breast cancer studies.

--Arvinas, Inc., a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended ...

The outperformance of Arvinas can be attributed to positive findings from a phase 1 study of its treatment for breast and prostate cancer. ARVN stock is also up 6x from levels of $13 seen in early ...

Arvinas uses its proprietary PROTAC ® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own ...

Arvinas Inc is today’s second Top Short. Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases.

Arvinas has advanced ARV-471 to a Phase 2 dose expansion trial testing it in patients with locally advanced or metastatic breast cancer that is ER positive and HER2 negative.

Arvinas Inc (NASDAQ:ARVN), a biotechnology company focused on developing therapies for cancer and other difficult-to-treat diseases, has been making waves in the pharmaceutical industry with its ...

So consider, for a moment, the misfortune of Arvinas, Inc. (NASDAQ:ARVN) investors who have held the stock for three years as it declined a whopping 72%. That'd be enough to cause even the ...